[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594451":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":44,"responsibleParty":58,"collaborators":60,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":42,"enrollmentInfo":73,"targetDuration":42,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":91,"overallStatus":102,"whyStopped":42,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"The University of Queensland","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","ACTIVE_COMPARATOR","Standard Non-Antimicrobial Hemodialysis Cap",[13],"Device: B Braun Combi-stopper",{"label":15,"type":16,"description":17,"interventionNames":18},"Intervention","EXPERIMENTAL","Antimicrobial Haemodialysis Catheter Luer End Cap",[19],"Device: ClearGuard HD",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","ClearGuard HD","The ClearGuard HD end cap is a male luer lock end cap that incorporates an antimicrobial treatment (Chlorhexidine) on its surface designed to reduce microbial colonisation within a haemodialysis catheter hub.",[15],[27],"Haemodialysis Catheter Luer End Cap",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"B Braun Combi-stopper","Standard practice caps used within the Metro North Kidney Health Service",[9],[11],[34],{"name":35,"affiliation":5,"role":36},"Claire Rickard","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Jue (Jenny) Wang","CONTACT","+61 450 184 498",null,"jue.wang@health.qld.gov.au",[45],{"facility":46,"status":42,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":42},"Royal Brisbane and Women's Hospital","Herston","Queensland","4029","Australia","AU",{"type":53,"coordinates":54},"Point",[55,56],153.01852,-27.44453,{"lat":56,"lon":55},{"type":59,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR",[61],{"name":46,"class":62},"OTHER_GOV","100594451","chlorhexidine-caps-for-clabsi-prevention-in-hemodialysis-a-pilot-randomized-controlled-trial-100594451",false,"NCT07019610","Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial","Evaluation of Chlorhexidine Caps for Central Line Associated Blood Stream Infection Prevention in People Needing Hemodialysis: a Pilot Randomised Control Trial","ECHO-HD","Inclusion Criteria:\n\n* Age≥18\n* Able to provide informed consent\n* Kidney failure requiring a tunnelled CVC for treatment (haemodialysis)\n* 21 days BSI free\n* No known allergy to chlorhexidine and\u002For nylon and\u002For polypropylene.\n\nExclusion Criteria:\n\n* Current CLABSI\n* Known allergic to chlorhexidine and\u002For nylon and\u002For polypropylene.\n* Patients on an end-of-life pathway\n* People with a cognitive impairment and\u002For intellectual disability","ALL","18 Years",{"count":74,"type":75},60,"ESTIMATED","INTERVENTIONAL",[78],"NA","The goal of this clinical trial is to compare a chlorhexidine antimicrobial barrier cap in patients requiring hemodialysis treatment to the standard hemodialysis caps currently used within the Metro North Kidney Health Service.\n\nThe main questions to answer are:\n\n* Study Feasibility\n* Occurrence of infectious complications related to renal central venous catheters\n\nParticipants will be randomly allocated to receive either of the below hemodialysis caps to cover their hemodialysis catheter hub:\n\n* The standard hemodialysis cap used at the Royal Brisbane and Women's Hospital, or\n* The intervention hemodialysis cap containing chlorhexidine inside it\n\nResearchers will compare standard and chlorhexidine hemodialysis caps to see if the presence of chlorhexidine improves the occurrance of infectious complications related to the hemodialysis catheter.",[81,82,83,84,85,86,87,88,89,90],"Vascular Access Complication","Device Related Infection","Device Related Sepsis","Catheter Infection","Catheter Complications","Catheter-Related Infections","Catheter Related Complications","Hemodialysis Catheter Infection","Hemodialysis Catheter-associated Infection","Hemodialysis Complication",[92,93,94,95,96,97,98,99,100,101],"Hemodialysis Catheter","Randomised Controlled Trial","Antimicrobial Barrier Caps","Vascular access device","Hemodialysis catheter caps","Chlorhexidine cap","Central Venous Catheter","CVC","CLABSI","Central Line Associated Blood Stream Infection","NOT_YET_RECRUITING","2026-04-27",{"date":105,"type":106},"2026-04-29","ACTUAL",{"date":108,"type":75},"2026-06",{"date":110,"type":75},"2028-02",{"name":5,"class":6},1]